Texas THC Regulations: Medical Cannabis Laws and Hemp-Derived Products

Executive Summary

Texas implemented sweeping new THC regulations on July 31, 2026, marking the most significant shift in the state's cannabis policy since the 2019 expansion of the Compassionate Use Program. The new rules establish a comprehensive regulatory framework for hemp-derived THC products, impose strict potency limits, and create a state licensing system for manufacturers and retailers. Under the regulations, products containing delta-8 THC, delta-9 THC, and other hemp-derived cannabinoids must not exceed 0.5% total THC by dry weight, significantly lower than the 0.3% delta-9 THC limit established by the 2018 Farm Bill. The Texas Department of State Health Services (DSHS) will oversee licensing, testing, and enforcement, with civil penalties ranging from $1,000 to $25,000 per violation. The regulations affect an estimated 2,500 retailers statewide and a hemp-derived cannabinoid market valued at approximately $800 million annually in Texas. Medical cannabis patients enrolled in the Compassionate Use Program remain exempt from certain restrictions, with access to products containing up to 1% total THC. The implementation follows two years of legislative debate and represents a compromise between prohibitionist lawmakers and the burgeoning hemp industry.

Why This Matters

The Texas THC regulations affect millions of consumers, thousands of businesses, and set a precedent for how conservative states navigate the gap between federal hemp law and state cannabis prohibition. Texas is the second-largest state by population with approximately 30 million residents, making its regulatory approach influential across the South and Midwest. The rules directly impact an estimated 50,000 Texans enrolled in the Compassionate Use Program who rely on medical cannabis for conditions including epilepsy, PTSD, cancer, and chronic pain.

For the cannabis industry, Texas represents a critical market. The state's hemp-derived cannabinoid sector generated an estimated $800 million in sales during 2025, according to the Texas Hemp Coalition. The new regulations force approximately 2,500 retail locations—including smoke shops, convenience stores, and dedicated hemp retailers—to either comply with strict testing and labeling requirements or exit the market entirely. Industry analysts project that 30-40% of current retailers may close due to compliance costs.

Economically, the regulations create winners and losers. Established multi-state operators with existing compliance infrastructure can absorb the estimated $50,000 to $150,000 in initial licensing and testing costs, while small operators face existential challenges. The Texas Hemp Growers Association estimates that 200-300 small farms cultivating hemp for cannabinoid extraction may be forced out of business within the first year.

Politically, Texas serves as a bellwether for Republican-controlled states grappling with hemp-derived THC products that exist in a legal gray area. The state's approach—strict regulation rather than outright prohibition—may influence similar efforts in Florida, Georgia, and Tennessee, where legislators have proposed comparable frameworks. Patient advocates view the regulations as a mixed outcome: tighter controls provide consumer safety protections but also restrict access to products that many Texans have used for years without incident.

Background and History

Texas cannabis policy evolved from absolute prohibition to limited medical access over two decades, with hemp-derived THC products creating an unregulated market that ultimately forced legislative action.

Early Prohibition Era (1931-2015)

Texas criminalized cannabis possession in 1931 under the Texas Controlled Substances Act, codified in Chapter 481 of the Texas Health and Safety Code. For more than 80 years, possession of any amount remained a criminal offense, with penalties ranging from Class B misdemeanors for small amounts to felony charges for larger quantities. The state maintained some of the strictest enforcement in the nation, with more than 60,000 annual arrests for cannabis possession during the early 2000s.

Legislative reform efforts repeatedly failed in the Texas Legislature, which meets biennially for 140-day sessions. Between 2000 and 2015, at least 15 bills proposing medical cannabis access or decriminalization died in committee, reflecting the conservative composition of the Legislature and opposition from law enforcement groups including the Texas Municipal Police Association and the Combined Law Enforcement Associations of Texas (CLEAT).

Compassionate Use Act (2015)

The breakthrough came in 2015 when the 84th Texas Legislature passed the Compassionate Use Act, signed into law by Governor Greg Abbott on June 1, 2015. The legislation, codified as Texas Health and Safety Code § 169.001 et seq., created the nation's most restrictive medical cannabis program. Initially, the program allowed only patients with intractable epilepsy to access low-THC cannabis oil containing no more than 0.5% THC and at least 10% CBD.

The Texas Department of Public Safety (DPS) received regulatory authority, issuing just three licenses to cultivate, process, and dispense low-THC cannabis. The first dispensaries opened in 2017, serving fewer than 1,000 patients in the initial year. Advocates including the Epilepsy Foundation of Texas and Texans for Responsible Marijuana Policy pushed for broader access, but expansion remained politically challenging.

Program Expansion (2019)

The 86th Legislature expanded the Compassionate Use Program in 2019 through House Bill 3703, effective September 1, 2019. The legislation added qualifying conditions including multiple sclerosis, Parkinson's disease, ALS, terminal cancer, autism, and incurable neurodegenerative diseases. The THC cap increased from 0.5% to 1% by weight, and the CBD minimum requirement was eliminated. Enrollment grew to approximately 6,000 patients by the end of 2019.

Separately, House Bill 1325 aligned Texas law with the 2018 Farm Bill by legalizing hemp cultivation and hemp-derived products containing no more than 0.3% delta-9 THC on a dry weight basis. The legislation, which took effect immediately upon Governor Abbott's signature on June 10, 2019, created the framework for a legal hemp industry but inadvertently opened the door for hemp-derived intoxicating cannabinoids.

The Delta-8 Boom (2020-2023)

Beginning in 2020, retailers across Texas began selling delta-8 THC products, a hemp-derived cannabinoid that produces intoxicating effects similar to traditional delta-9 THC. Manufacturers argued that delta-8 THC derived from hemp and containing less than 0.3% delta-9 THC met the legal definition of hemp under both federal and Texas law. The market exploded, with delta-8 products appearing in gas stations, smoke shops, and dedicated retailers.

The Texas Department of State Health Services attempted to ban delta-8 THC in October 2021, adding it to the state's Schedule I controlled substances list. However, the hemp industry sued, and on February 23, 2022, Travis County District Judge Jan Soifer issued a temporary injunction blocking the ban. The case, Hometown Hero CBD v. Texas Department of State Health Services, remained in litigation through 2023, leaving delta-8 in legal limbo but widely available.

Legislative Response (2023-2025)

The 88th Legislature in 2023 considered multiple bills to regulate hemp-derived cannabinoids but failed to pass comprehensive legislation before the session ended on May 29, 2023. House Bill 2593 and Senate Bill 1008 both died in committee amid disagreements between prohibitionist lawmakers, the hemp industry, and medical cannabis advocates.

The breakthrough came during the 89th Legislature in 2025. Senate Bill 645, authored by Senator Charles Schwertner (R-Georgetown) and co-sponsored by Senator José Menéndez (D-San Antonio), established a comprehensive regulatory framework for hemp-derived THC products. The bill passed the Senate 21-10 on April 15, 2025, and the House 89-58 on May 20, 2025. Governor Abbott signed it into law on June 5, 2025, with an effective date of July 31, 2026, providing a 14-month implementation period.

Rulemaking Process (2025-2026)

Senate Bill 645 directed the Texas Department of State Health Services to develop implementing regulations through the standard rulemaking process outlined in the Texas Administrative Procedure Act. DSHS published proposed rules in the Texas Register on October 15, 2025, triggering a 30-day public comment period. The agency received more than 8,000 comments from industry stakeholders, consumers, physicians, and advocacy groups.

Key controversies during rulemaking included the 0.5% total THC limit (industry groups advocated for 1-2%), testing requirements (small manufacturers argued costs were prohibitive), and the prohibition on certain product forms including gummies shaped like animals or cartoon characters. DSHS adopted final rules on March 1, 2026, published in the Texas Register on March 15, 2026, with the July 31, 2026 effective date unchanged.

Key Players

Texas Department of State Health Services (DSHS)

DSHS serves as the primary regulatory authority for hemp-derived THC products under the new framework. The agency's responsibilities include licensing manufacturers, processors, and retailers; establishing testing standards; conducting inspections; and enforcing compliance. Commissioner Jennifer Shuford, appointed by Governor Abbott in 2024, oversees implementation. DSHS created a new Hemp Cannabinoid Regulation Division with an initial budget of $12 million for fiscal year 2027, funded through licensing fees and civil penalties. The division employs 35 staff members including compliance officers, laboratory scientists, and administrative personnel.

Texas Department of Public Safety (DPS)

DPS retains authority over the Compassionate Use Program for medical cannabis, operating separately from the DSHS hemp regulations. The agency licenses the three existing medical cannabis dispensaries—Compassionate Cultivation, Surterra Wellness Texas, and Goodblend Texas—and maintains the Compassionate Use Registry of Texas (CURT), which enrolled approximately 50,000 patients as of July 2026. DPS also enforces criminal penalties for THC products that exceed legal limits or lack proper licensing.

Texas Hemp Coalition

The Texas Hemp Coalition represents approximately 400 hemp farmers, processors, and retailers statewide. Executive Director Zachary Maxwell has been the industry's primary voice during the regulatory process, advocating for higher THC limits and lower compliance costs. The coalition supported Senate Bill 645 as a compromise that provided regulatory clarity while preserving market access, though Maxwell publicly stated that the 0.5% THC limit was "more restrictive than scientifically justified." The organization has pledged $2 million to help small operators cover initial compliance costs through a grant program.

Texans for Responsible Marijuana Policy

This advocacy organization, led by Executive Director Heather Fazio, represents medical cannabis patients and supports broader legalization. The group opposed certain aspects of the new regulations, particularly restrictions that Fazio said "create unnecessary barriers for patients who have found relief through hemp-derived products." The organization supported amendments that would have exempted medical cannabis patients from the 0.5% limit but ultimately accepted the final framework as incremental progress. Texans for Responsible Marijuana Policy continues to advocate for full adult-use legalization.

Combined Law Enforcement Associations of Texas (CLEAT)

CLEAT, representing more than 20,000 law enforcement officers, supported the regulatory framework as a necessary response to the proliferation of intoxicating hemp products. Executive Director Charley Wilkison testified before legislative committees that the unregulated delta-8 market created enforcement challenges and public safety concerns. The organization advocated for even stricter limits and supported criminal penalties for unlicensed sales, positions that were partially incorporated into the final regulations.

Texas Medical Association

The state's largest physician organization, representing more than 55,000 doctors, took a neutral position on the regulations while emphasizing the need for physician oversight of medical cannabis access. President Rick Snyder II, M.D., issued a statement supporting "evidence-based regulation that protects patient safety while allowing appropriate medical access." The association successfully lobbied for provisions requiring medical cannabis recommendations to come from physicians with a bona fide doctor-patient relationship.

Legal and Regulatory Framework

The Texas THC regulatory system rests on three legal pillars: federal hemp law, state statute, and administrative rules that together create a complex compliance landscape.

Federal Foundation: The 2018 Farm Bill

The Agricultural Improvement Act of 2018, commonly known as the 2018 Farm Bill, removed hemp from the Controlled Substances Act's Schedule I classification. Section 10113 of the Farm Bill, codified at 7 U.S.C. § 1639o, defines hemp as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis. This federal definition created the legal space for hemp-derived cannabinoids, including delta-8 THC, delta-10 THC, and THCA, which technically comply with the delta-9 THC limit while still producing intoxicating effects.

The Farm Bill explicitly preserves state authority to regulate hemp more restrictively than federal law. Section 10114 states that nothing in the legislation "prohibits a State or Indian Tribe from adopting a law that is more stringent than this subtitle." Texas exercised this authority through Senate Bill 645.

State Statute: Senate Bill 645

Senate Bill 645, codified as amendments to Texas Health and Safety Code Chapter 443, establishes the statutory framework for hemp-derived cannabinoid regulation. Key provisions include:

Total THC Limit: Products may not contain more than 0.5% total THC by dry weight, calculated as the sum of delta-9 THC, delta-8 THC, delta-10 THC, THCA, and other THC isomers. This "total THC" approach differs from the federal focus on delta-9 THC alone and effectively restricts products that were previously legal under the Farm Bill's definition.

Licensing Requirements: Manufacturers, processors, and retailers must obtain licenses from DSHS. License fees are set at $5,000 annually for manufacturers, $3,000 for processors, and $1,000 for retailers. Applicants must pass background checks, demonstrate financial responsibility, and maintain $1 million in general liability insurance.

Testing Mandates: All products must be tested by DSHS-approved laboratories for cannabinoid potency, heavy metals, pesticides, microbial contaminants, and residual solvents. Testing must occur for each batch, defined as products manufactured in a single production run. Test results must be available to consumers through QR codes on product packaging.

Age Restrictions: Sales to persons under 21 are prohibited, with exceptions for medical cannabis patients enrolled in the Compassionate Use Program who may be as young as 18 with parental consent for certain conditions.

Product Restrictions: The statute bans products "designed to appeal to minors," including gummies shaped like animals, fruits, or cartoon characters; products with packaging resembling candy brands; and products with added flavors "primarily appealing to persons under 21." Inhalable products must include warnings about respiratory risks.

Enforcement and Penalties: DSHS may impose civil penalties of $1,000 to $25,000 per violation, suspend or revoke licenses, and issue cease-and-desist orders. Criminal penalties under Texas Health and Safety Code § 481.121 apply to possession or sale of products exceeding the 0.5% total THC limit, with penalties ranging from Class B misdemeanors to state jail felonies depending on quantity.

Administrative Rules: 25 TAC Chapter 229

The Texas Department of State Health Services adopted comprehensive implementing regulations published as Title 25 of the Texas Administrative Code, Chapter 229. The rules, spanning 87 pages in the Texas Register, provide detailed requirements for:

Laboratory Certification: Testing laboratories must achieve ISO/IEC 17025 accreditation and register with DSHS. As of July 31, 2026, only 12 laboratories in Texas meet the requirements, creating a potential bottleneck. Labs must use validated testing methods with detection limits of 0.01% for cannabinoids and specified limits for contaminants.

Labeling Standards: Products must display total THC content as a percentage and in milligrams per serving, a scannable QR code linking to test results, a unique batch identifier, manufacturing and expiration dates, and warnings including "This product contains THC and may cause intoxication" and "For adult use only—keep out of reach of children."

Record-Keeping: Licensees must maintain records for five years documenting product sourcing, manufacturing processes, testing results, inventory tracking, and sales transactions. Records must be available for DSHS inspection within 24 hours of request.

Advertising Restrictions: Marketing cannot make health claims not approved by the FDA, target minors, or appear on billboards within 1,000 feet of schools or playgrounds. Social media advertising must include age-gating mechanisms.

Interaction with Federal Law

The Texas regulations create a state-legal market for products that may violate federal law. While the 2018 Farm Bill legalized hemp, the Food and Drug Administration maintains that adding THC to food products violates the Federal Food, Drug, and Cosmetic Act. The FDA has not actively enforced this position, but the legal ambiguity creates risk for interstate commerce. Texas products cannot legally cross state lines, and financial institutions remain hesitant to serve hemp-derived THC businesses due to federal banking restrictions.

State-by-State Breakdown

Texas joins a patchwork of state approaches to hemp-derived THC, with regulatory frameworks ranging from outright bans to minimal oversight.

Texas

Status: Regulated market with 0.5% total THC limit, effective July 31, 2026. Medical cannabis available through Compassionate Use Program with up to 1% total THC for approximately 50,000 enrolled patients. Adult-use cannabis remains illegal with criminal penalties.

Key Dates: Compassionate Use Act signed June 1, 2015; hemp legalized June 10, 2019; Senate Bill 645 signed June 5, 2025; regulations effective July 31, 2026.

Possession Limits: No specified limit for hemp-derived products meeting the 0.5% threshold. Medical cannabis patients may possess a 90-day supply as determined by their physician. Possession of products exceeding 0.5% total THC without medical authorization remains criminal.

California

Status: Adult-use cannabis legal since 2016; hemp-derived THC products regulated as cannabis and must be sold through licensed dispensaries. Assembly Bill 45, effective January 1, 2024, brought all intoxicating hemp products under the Department of Cannabis Control's jurisdiction.

Key Dates: Proposition 64 passed November 8, 2016; adult-use sales began January 1, 2018; hemp-derived THC regulations effective January 1, 2024.

Possession Limits: Adults 21+ may possess up to 28.5 grams of cannabis flower or 8 grams of concentrate, including hemp-derived products. Medical patients with recommendations may possess larger amounts.

New York

Status: Adult-use cannabis legal since 2021; hemp-derived THC products subject to Office of Cannabis Management oversight. Regulations adopted in 2023 require cannabinoid hemp products to be sold only through licensed retailers with testing and labeling requirements similar to cannabis.

Key Dates: Marijuana Regulation and Taxation Act signed March 31, 2021; cannabinoid hemp regulations effective October 1, 2023.

Possession Limits: Adults 21+ may possess up to 3 ounces of cannabis flower or 24 grams of concentrate. Hemp-derived products count toward these limits.

Florida

Status: Medical cannabis legal; hemp-derived delta-8 THC banned. Florida Statute § 381.986 restricts THC products to the medical marijuana program. Delta-8 and similar cannabinoids are classified as controlled substances. Adult-use legalization appears on the November 2026 ballot as Amendment 3.

Key Dates: Medical cannabis approved by voters November 8, 2016; delta-8 ban effective July 1, 2023.

Possession Limits: Medical patients may possess up to a 70-day supply as determined by their physician, typically 2.5 ounces of flower every 35 days. Non-patients may not legally possess THC products.

Ohio

Status: Adult-use cannabis legal as of December 7, 2023, following passage of Issue 2. Hemp-derived THC products remain in regulatory limbo pending state rulemaking. The Ohio Department of Commerce is developing regulations to integrate hemp-derived products into the cannabis framework.

Key Dates: Medical program launched January 16, 2019; Issue 2 passed November 7, 2023; adult-use sales expected to begin late 2024.

Possession Limits: Adults 21+ may possess up to 2.5 ounces of cannabis flower or 15 grams of concentrate. Medical patients may possess a 90-day supply.

Tennessee

Status: Hemp-derived delta-8 THC legal but unregulated. Multiple bills to restrict or regulate these products have failed in the Tennessee General Assembly. Medical cannabis remains illegal except for a limited CBD oil program for intractable seizures.

Key Dates: Hemp legalized July 1, 2019; delta-8 regulation bills failed in 2022, 2023, and 2024 sessions.

Possession Limits: No specified limits for hemp-derived products. Cannabis possession remains criminal with penalties starting at a Class A misdemeanor for casual exchange.

Georgia

Status: Low-THC medical cannabis oil legal for registered patients; hemp-derived delta-8 THC in legal gray area. The Georgia Department of Agriculture regulates hemp but has not addressed intoxicating cannabinoids. Legislation to regulate delta-8 has been proposed but not enacted.

Key Dates: Haleigh's Hope Act passed April 16, 2015; expanded to allow in-state production March 24, 2019.

Possession Limits: Medical patients may possess up to 20 fluid ounces of low-THC oil (no more than 5% THC). Possession of cannabis flower remains a misdemeanor.

Market and Business Implications

The Texas regulations create a bifurcated market where well-capitalized operators gain competitive advantages while small businesses face consolidation or closure.

Compliance Costs and Market Consolidation

Industry analysts estimate that achieving full compliance with the new Texas regulations requires $50,000 to $150,000 in initial investment for retailers, depending on inventory size and existing infrastructure. Costs include licensing fees ($1,000 annually), product testing ($200-$500 per batch), liability insurance ($3,000-$8,000 annually), labeling updates, point-of-sale system modifications, and legal consultation. For manufacturers and processors, costs escalate to $200,000-$500,000 when accounting for facility upgrades, laboratory equipment, and quality control personnel.

The Texas Hemp Coalition projects that 30-40% of current retailers will exit the market within 12 months of the regulations taking effect. Small operators with annual revenues below $250,000 face the steepest challenges, as compliance costs consume a disproportionate share of revenue. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries view Texas as a strategic expansion opportunity, with the regulatory framework favoring established players who have navigated similar compliance regimes in other states.

Testing Laboratory Bottleneck

The requirement for ISO/IEC 17025-accredited laboratories creates a significant bottleneck. As of July 31, 2026, only 12 laboratories in Texas meet DSHS certification requirements, with a combined testing capacity of approximately 5,000 samples per month. With an estimated 2,500 retailers each carrying an average of 50 SKUs and quarterly batch testing requirements, the market requires testing of approximately 125,000 samples quarterly, or 41,667 per month—more than eight times current capacity.

Testing costs have increased from an average of $150 per sample in early 2026 to $400-$500 per sample by July 2026 due to demand. Turnaround times have extended from 5-7 days to 3-4 weeks, creating inventory management challenges. Several national testing companies including Steep Hill Labs and SC Labs have announced plans to open Texas facilities, but full buildout will require 12-18 months. The laboratory shortage may force DSHS to implement a phased enforcement approach, prioritizing high-volume manufacturers.

Product Reformulation and SKU Reduction

The 0.5% total THC limit requires extensive product reformulation. Products previously marketed as containing 10-25 milligrams of delta-8 THC per serving must be reduced to 5 milligrams or less to comply with the percentage limit when accounting for serving size. Manufacturers report that reducing potency below consumer expectations may drive customers to illicit markets or neighboring states with less restrictive laws.

Industry data indicates that retailers have reduced SKU counts by an average of 60%, discontinuing products that cannot be reformulated economically or that violate form restrictions. Gummy products, which represented approximately 40% of hemp-derived THC sales in Texas during 2025, have been particularly affected by the ban on shapes and flavors appealing to minors. Manufacturers have shifted toward tinctures, capsules, and unflavored edibles, though consumer acceptance remains uncertain.

Impact on Medical Cannabis Dispensaries

The three licensed medical cannabis dispensaries—Compassionate Cultivation, Surterra Wellness Texas, and Goodblend Texas—operate under separate regulations administered by the Texas Department of Public Safety. These vertically integrated operators cultivate, process, and dispense medical cannabis to the approximately 50,000 patients enrolled in the Compassionate Use Program. Medical products may contain up to 1% total THC, double the limit for hemp-derived products.

Dispensary operators initially feared that hemp-derived products would cannibalize medical sales, but the 0.5% limit reduces this competitive threat. Compassionate Cultivation CEO Morris Denton stated in a July 2026 interview with the Austin American-Statesman that the regulations "create appropriate separation between medical cannabis, which requires physician oversight, and lower-potency hemp products for adult use." Medical dispensaries reported 15% year-over-year patient growth during the first half of 2026, suggesting that the Compassionate Use Program continues to serve patients seeking higher-potency products and medical guidance.

Interstate Commerce Restrictions

Texas hemp-derived THC products cannot legally cross state lines due to federal restrictions and varying state laws. This prohibition on interstate commerce increases costs by requiring in-state manufacturing and limiting economies of scale. Several national hemp companies including Charlotte's Web and Lazarus Naturals have announced plans to establish Texas manufacturing facilities to serve the state market, representing capital investments of $10-$50 million per facility.

The interstate commerce restriction also affects raw material sourcing. While hemp biomass can be imported from other states, finished products containing THC cannot. This creates opportunities for Texas hemp farmers, who can supply in-state manufacturers. The Texas Department of Agriculture reported that hemp cultivation acreage increased 35% in 2026 to approximately 8,500 acres, driven by anticipated demand for cannabinoid extraction.

Tax Revenue Projections

Unlike adult-use cannabis states that impose excise taxes on THC products, Texas does not levy a specific tax on hemp-derived cannabinoids beyond standard sales tax. The state comptroller's office projects that the regulated hemp-derived THC market will generate $48-$52 million in annual sales tax revenue at the current 6.25% state rate, plus additional local sales taxes. Licensing fees are expected to contribute $8-$10 million annually to DSHS for regulatory administration.

Some legislators have proposed a 10% excise tax on hemp-derived THC products to fund substance abuse treatment and prevention programs, but no such legislation has advanced. The Texas Hemp Coalition opposes additional taxation, arguing that high tax rates would perpetuate illicit markets, as seen in California and other high-tax states.

What Experts Say

Stakeholders across the cannabis policy spectrum view the Texas regulations as a pragmatic compromise that addresses safety concerns while preserving market access, though opinions diverge on whether the framework is too restrictive or too permissive.

Zachary Maxwell, executive director of the Texas Hemp Coalition, characterized the regulations as "a workable framework that provides legal clarity for an industry that has operated in uncertainty for too long," according to his testimony before the Texas House Public Health Committee in March 2025. Maxwell acknowledged that the 0.5% total THC limit is "more restrictive than we advocated for" but emphasized that "a regulated market is preferable to prohibition or continued legal ambiguity."

Heather Fazio, executive director of Texans for Responsible Marijuana Policy, expressed concern that the regulations "create unnecessary barriers for patients who have found relief through hemp-derived products" in a statement released on July 30, 2026. Fazio noted that many medical cannabis patients cannot afford the costs associated with the Compassionate Use Program, which requires physician consultations and higher-priced dispensary products. She advocated for exempting medical patients from the 0.5% limit and allowing physicians to recommend hemp-derived products as an alternative to prescription medications.

Dr. Sunil Aggarwal, a palliative care physician and cannabis researcher based in Seattle, reviewed the Texas regulations at CannIntel's request and observed that the total THC measurement approach "represents a more scientifically sound method than focusing solely on delta-9 THC, as it accounts for all intoxicating cannabinoids." However, Dr. Aggarwal questioned whether the 0.5% threshold "is supported by evidence regarding impairment or safety risks, or whether it represents a political compromise rather than a science-based determination."

Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws (NORML), stated in a July 2026 blog post that Texas "joins a growing number of states attempting to regulate a market created by the unintended consequences of the 2018 Farm Bill." Armentano argued that "the proliferation of intoxicating hemp products demonstrates the absurdity of maintaining cannabis prohibition while allowing chemically similar compounds derived from hemp" and called for comprehensive federal cannabis legalization to resolve the regulatory patchwork.

From a law enforcement perspective, Charley Wilkison, executive director of the Combined Law Enforcement Associations of Texas, supported the regulations as "a necessary step to address public safety concerns created by the unregulated sale of intoxicating products in gas stations and convenience stores," according to his testimony before the Texas Senate Health and Human Services Committee in February 2025. Wilkison emphasized the importance of age restrictions and testing requirements to prevent youth access and ensure product safety.

Industry consultant Bethany Moore, founder of the cannabis business advisory firm Peakstone Strategies, analyzed the Texas market in a July 2026 report and concluded that "the regulatory framework will accelerate consolidation and professionalization of the hemp-derived cannabinoid industry." Moore projected that "within 24 months, the Texas market will be dominated by 10-15 major operators with multi-state compliance experience, while hundreds of small retailers will have exited or been acquired."

What's Next

The implementation of Texas THC regulations triggers a 12-18 month transition period during which market structure, enforcement priorities, and potential legislative adjustments will take shape.

Immediate Implementation (August-December 2026)